TC
PTCT icon

TFS Capital’s PTC Therapeutics PTCT Stock Holding History

TFS Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-23,831
Closed -$1.05M – 1115
2014
Q3 		$1.05M Buy
+23,831
New +$746K 0.09% 358
2014
Q2 		– Sell
-9,289
Closed -$243K – 1315
2014
Q1 		$243K Buy
+9,289
New +$250K 0.02% 1114

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

TFS Capital's PTCT Position: Q4 2014 in Review

TFS Capital sold out of PTC Therapeutics (PTCT) in Q4 2014, closing a stake of 23,831 shares — an estimated $1.05M sold.

TFS Capital first reported a position in PTCT in Q1 2014 and held it in 2 quarters. The position peaked at $1.05M in Q3 2014. 132 funds tracked by Wall St. Rank hold PTCT as of Q4 2014.

  • TFS Capital reported no remaining PTC Therapeutics position as of Q4 2014 after selling out during the quarter.
  • TFS Capital sold 23,831 PTC Therapeutics shares in Q4 2014, an estimated $1.05M.
  • TFS Capital first reported a position in PTC Therapeutics in Q1 2014 and held it in 2 quarters.
  • TFS Capital's PTC Therapeutics position peaked at $1.05M in Q3 2014.
  • 132 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2014.

Based on TFS Capital's 13F filing for Q4 2014, filed 29 Jan 2015.